Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Gabriel Rebick & Sharon L Walmsley. (2012) Issues in resistance, adherence, and comparative efficacy of the single-tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection. Virus Adaptation and Treatment 4, pages 51-63.
Read now
Read now
Timothy Juday, Kristy Grimm, Annette Zoe-Powers, James Willig & Edward Kim. (2011) A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care 23:9, pages 1154-1162.
Read now
Read now
Fabienne Marcellin, Raoul Moh, Maria Patrizia Carrieri, Christine Danel, Camelia Protopopescu, Delphine Gabillard, Bruno Spire & Xavier Anglaret. (2008) Depressive Symptoms and Exposure to Efavirenz in West African HIV-Infected Adults. HIV Clinical Trials 9:6, pages 445-447.
Read now
Read now
Gabriele Arendt, Dominique de Nocker, Hans-Juergen von Giesen & Thorsten Nolting. (2007) Neuropsychiatric side effects of efavirenz therapy. Expert Opinion on Drug Safety 6:2, pages 147-154.
Read now
Read now
Articles from other publishers (41)
Wei Hua, Sen Wang, Xi Wang, Ying Shao, Yali Wang, Jiangzhu Ye, Bin Su, Taiyi Jiang, Tong Zhang, Hao Wu, An Liu, Qunhui Li, Supriya D. Mahajan, Zaicun Li, Lijun Sun & Lili Dai. (2021) Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study. Frontiers in Psychiatry 12.
Crossref
Crossref
Johnson Kai Chun LawLaurie T. ButlerMatthew M. Hamill. (2020) Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom. AIDS Research and Human Retroviruses 36:6, pages 459-466.
Crossref
Crossref
Isaac O. Abah, Nondumiso B.Q. Ncube, Hazel A. Bradley, Oche O. AgbaJi & Phyllis Kanki. (2019) Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. Current HIV Research 16:6, pages 436-446.
Crossref
Crossref
Marion Sumari-de Boer, Arnt Schellekens, Ashanti Duinmaijer, Julieth M. Lalashowi, Happiness J. Swai, Quirijn de Mast, Andre van der Ven & Grace Kinabo. (2018) Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania. Tropical Medicine & International Health 23:2, pages 164-172.
Crossref
Crossref
Amanda Häggblom, Stefan Lindbäck, Magnus Gisslén, Leo Flamholc, Bo Hejdeman, Andreas Palmborg, Amy Leval, Eva Herweijer, Sverrir Valgardsson & Veronica Svedhem. (2017) HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. PLOS ONE 12:2, pages e0171227.
Crossref
Crossref
Glenn J. Treisman & Olivia Soudry. (2016) Neuropsychiatric Effects of HIV Antiviral Medications. Drug Safety 39:10, pages 945-957.
Crossref
Crossref
Jacinta Nwamaka Nwogu, Qing Ma, Chinedum Peace Babalola, Waheed Adeola Adedeji, Gene D. Morse & Babafemi Taiwo. (2016) Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals. AIDS Research and Treatment 2016, pages 1-13.
Crossref
Crossref
Michelle L. Giles, Marin C. Zapata, Stephen T. Wright, Kathy Petoumenos, Miriam Grotowski, Jennifer Broom, Matthew G. Law & Catherine C. O'Connor. (2016) How do outcomes compare between women and men living with HIV in Australia? An observational study. Sexual Health 13:2, pages 155.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
25
31
.
. (2014) Single-Pill Regimens for HIV-1 Infection. New England Journal of Medicine 371:19, pages 1844-1846.
Crossref
Crossref
Alison J. Hughes, Christine L. Mattson, Susan Scheer, Linda Beer & Jacek Skarbinski. (2014) Discontinuation of Antiretroviral Therapy Among Adults Receiving HIV Care in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 66:1, pages 80-89.
Crossref
Crossref
Liselotte Pochard, Laurent Hauviller, Lise Cuzin, Fréderic Eyvrard, Agnès Sommet, Jean-Louis Montastruc & Haleh Bagheri. (2014) Apport du logiciel Nadis® dans la collecte des effets indésirables des antirétroviraux : expérience en Midi-Pyrénées. Therapies 69:2, pages 149-155.
Crossref
Crossref
Michael S. Abers, Wayne X. Shandera & Joseph S. Kass. (2013) Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. CNS Drugs 28:2, pages 131-145.
Crossref
Crossref
AM Mills, A Antinori, B Clotet, J Fourie, G Herrera, C Hicks, JV Madruga, S Vanveggel, M Stevens & K Boven. (2013)
Neurological and psychiatric tolerability of rilpivirine (TMC278)
vs.
efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks
. HIV Medicine 14:7, pages 391-400.
Crossref
Crossref
. (2013) Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS 27:5, pages 803-813.
Crossref
Crossref
Antonella d'Arminio Monforte, Jane Anderson & Anita Olczak. (2012) What Do We Know about Antiretroviral Treatment of HIV in Women?. Antiviral Therapy 18:2_suppl, pages 27-34.
Crossref
Crossref
Claudia P. Cortes, Marco Siccardi, Ammara Chaikan, Andrew Owen, Guijun Zhang & Charles J. L. la Porte. (2013) Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. Therapeutic Drug Monitoring 35:1, pages 78-83.
Crossref
Crossref
Mona R Loutfy, Lorraine Sherr, Ulrike Sonnenberg-Schwan, Sharon L Walmsley, Margaret Johnson & Antonella d'Arminio Monforte. (2013) Caring for women living with HIV: gaps in the evidence. Journal of the International AIDS Society 16:1, pages 18509.
Crossref
Crossref
Kristina Thorsteinsson, Steen Ladelund, Søren Jensen-Fangel, Isik Somuncu Johansen, Terese L Katzenstein, Gitte Pedersen, Merete Storgaard, Niels Obel & Anne-Mette Lebech. (2012) Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study. BMC Infectious Diseases 12:1.
Crossref
Crossref
Marysabel Pinto Telis Silveira, Marília Cruz Guttier, Cezar Arthur Tavares Pinheiro, Tatiana Vanessa Silveira Pereira, Ana Laura Sica Cruzeiro & Leila Beltrami Moreira. (2012) Depressive symptoms in HIV-infected patients treated with highly active antiretroviral therapy. Revista Brasileira de Psiquiatria 34:2, pages 162-167.
Crossref
Crossref
E. Jennifer EdelmanKirsha GordonMaria C. Rodriguez-BarradasAmy C. Justice, for the VACS Project Team. (2012) Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir. AIDS Patient Care and STDs 26:6, pages 312-319.
Crossref
Crossref
Marysabel Pinto Telis Silveira, Marília Cruz Guttier, Cezar Arthur Tavares Pinheiro, Tatiana Vanessa Silveira Pereira, Ana Laura Sica Cruzeiro & Leila Beltrami Moreira. (2012) Depressive symptoms in HIV-infected patients treated with highly active antiretroviral therapy. Revista Brasileira de Psiquiatria 34:2, pages 162-167.
Crossref
Crossref
Sofia A. Pereira, Riccardo Wanke, M. Matilde Marques, Emília C. Monteiro & Alexandra M.M. Antunes. 2012. Advances in Molecular Toxicology Volume 6. Advances in Molecular Toxicology Volume 6
1
39
.
Christopher A. Kenedi & Harold W. Goforth. (2011) A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS and Behavior 15:8, pages 1803-1818.
Crossref
Crossref
C. Wyen, H. Hendra, M. Siccardi, M. Platten, H. Jaeger, T. Harrer, S. Esser, J. R. Bogner, N. H. Brockmeyer, B. Bieniek, J. Rockstroh, C. Hoffmann, A. Stoehr, C. Michalik, V. Dlugay, A. Jetter, H. Knechten, H. Klinker, A. Skaletz-Rorowski, G. Fatkenheuer, D. Egan, D. J. Back, A. Owen, S. Dupke, A. Carganico, A. Baumgarten, S. Koeppe, P. Kreckel, E. Lauenroth-Mai, F. Schlote, C. Schuler, M. Freiwald, M. Rausch, J. Golz, A. Moll, M. Zeitz, N. Brockmeyer, M. Hower, S. Reuter, T. Harrer, S. Esser, S. Staszewski, A. Plettenberg, S. Fenske, T. Buhk, H.-J. Stellbrink, R. Schmidt, B. Kuhlmann, F. Mosthaf, A. Rieke, S. Scholten, H. Jaeger, E. Jaegel-Guedes, R. Volkert, W. Becker, H. Hartl, A. Mutz, A. Ulmer, B. Frietsch & M. Muller. (2011) Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy 66:9, pages 2092-2098.
Crossref
Crossref
Rubin Lubomirov, Sara Colombo, Julia di Iulio, Bruno Ledergerber, Raquel Martinez, Matthias Cavassini, Bernard Hirschel, Enos Bernasconi, Luigia Elzi, Pietro Vernazza, Hansjakob Furrer, Huldrych F. Günthard & Amalio Telenti. (2011) Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. The Journal of Infectious Diseases 203:2, pages 246-257.
Crossref
Crossref
L. Michel, V. Villes, F. Dabis, B. Spire, M. Winnock, M.-A. Loko, I. Poizot-Martin, M. A. Valantin, P. Bonnard, D. Salmon-Céron & M. P. Carrieri. (2009) Role of treatment for depressive symptoms in relieving the impact of fatigue in HIVâHCV co-infected patients: ANRS Co13 Hepavih, France, 2006â2008. Journal of Viral Hepatitis.
Crossref
Crossref
. 2009. Meyler's Side Effects of Psychiatric Drugs. Meyler's Side Effects of Psychiatric Drugs
647
718
.
Shaheena Asad, Todd Hulgan,Stephen P. Raffanti,Jim Daugherty,Wayne Ray,Timothy R. Sterling,. (2008) Sociodemographic Factors Predict Early Discontinuation of HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors. Journal of the National Medical Association 100:12, pages 1417-1424.
Crossref
Crossref
Rebecca K Lodwick, Colette J Smith, Mike Youle, Fiona C Lampe, Mervyn Tyrer, Sanjay Bhagani, Clinton Chaloner, Caroline A Sabin, Margaret A Johnson & Andrew N Phillips. (2008) Stability of antiretroviral regimens in patients with viral suppression. AIDS 22:9, pages 1039-1046.
Crossref
Crossref
Christopher Nyakutira, Daniel Röshammar, Emmanuel Chigutsa, Prosper Chonzi, Michael Ashton, Charles Nhachi & Collen Masimirembwa. (2007) High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. European Journal of Clinical Pharmacology 64:4, pages 357-365.
Crossref
Crossref
Elise D. Riley, Monica Gandhi, C. Bradley Hare, Jennifer Cohen & Stephen W. Hwang. (2007) Poverty, unstable housing, and HIV infection among women living in the United States. Current HIV/AIDS Reports 4:4, pages 181-186.
Crossref
Crossref
Colette J Smith, Caroline A Sabin, Mike S Youle, Fiona C Lampe, Sanjay Bhagani, Sara Madge, Dewi Puradiredja, Margaret A Johnson & Andrew N Phillips. (2007) Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:1, pages 62-67.
Crossref
Crossref
R. Morillo Verdugo, M.V. Gil Navarro, L. Abdel-Kader Martín, A. Castillo Muñoz, U. Baños Roldán & S. Artacho Criado. (2007) Análisis de las causas y factores predictivos de discontinuación del tratamiento con tenofovir en pacientes VIH pretratados. Farmacia Hospitalaria 31:4, pages 200-205.
Crossref
Crossref
Christoph Fux, John Evison, Matthias Schlegel, Christine Thurnheer & Hansjakob Furrer. 2007.
300
314
.
M. P. Carrieri, L. Amass, G. M. Lucas, D. Vlahov, A. Wodak & G. E. Woody. (2006) Buprenorphine Use: The International Experience. Clinical Infectious Diseases 43:Supplement 4, pages S197-S215.
Crossref
Crossref
Asha Persson & Christy Newman. (2006) Potency and vulnerability: Troubled ‘selves’ in the context of antiretroviral therapy. Social Science & Medicine 63:6, pages 1586-1596.
Crossref
Crossref
V. Journot, G. Chene, N. De Castro, C. Rancinan, J.-P. Cassuto, C. Allard, J.-L. Vilde, A. Sobel, M. Garre & J.-M. Molina. (2006) Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099. Clinical Infectious Diseases 42:12, pages 1790-1799.
Crossref
Crossref
David Burger, Ilse van der Heiden, Charles la Porte, Marchina van der Ende, Paul Groeneveld, Clemens Richter, Peter Koopmans, Frank Kroon, Herman Sprenger, Jan Lindemans, Paul Schenk & Ron van Schaik. (2006) Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British Journal of Clinical Pharmacology 61:2, pages 148-154.
Crossref
Crossref
Gabriele Arendt. (2006) Affective Disorders in Patients with HIV Infection. CNS Drugs 20:6, pages 507-518.
Crossref
Crossref
Barbara S. KoppelChetan Bharel. (2005)
Letter to the Editor:
Use of Amitriptyline to Offset Sleep Disturbances Caused by Efavirenz
. AIDS Patient Care and STDs 19:7, pages 419-420.
Crossref
Crossref
![Supercharge Your Next Research Paper: Research and write your next paper with Jenni AI.]({"type":"image" , "src" : "/sda/112443/Skyscraper-socialsciences.png"})